DalCor Pharmaceuticals, a company developing precision treatments by genetically targeting patients that will derive clinical benefits, has named Dr Fouzia Laghrissi-Thode as its director, it was reported yesterday.

The new director is vice-president at AstraZeneca. She has been leading the US Renal-Cardiology Therapeutic Area based in San Francisco and earlier led the Global Cardiovascular Metabolism Therapeutic Area.

In addition to her cardiovascular experience, Dr Laghrissi-Thode has demonstrated success at Roche, Novartis and Sandoz in clinical development, global strategic marketing, business development and licensing in various therapeutic areas including diabetes, renal and the central nervous system. She drove the development of Dalcetrapib and the Dal-HEART program at Roche. She also served as a board member of the Healthcare Businesswomen's Association Europe and was recognised by HBA in 2012 for her work in developing and promoting women leadership in healthcare.